0L3C Stock Chart & Stats
$85.67
-$0.36(-0.42%)
At close: 4:00 PM EDT
$85.67
-$0.36(-0.42%)
Day’s Range― - ―
52-Week Range$62.29 - $92.50
Previous CloseN/A
Volume26.00
Average Volume (3M)925.00
Market Cap
$9.77B
Enterprise Value$13.54K
Total Cash (Recent Filing)$157.00M
Total Debt (Recent Filing)$3.81B
Price to Earnings (P/E)25.7
Beta0.84
Next Earnings
Nov 03, 2026EPS Estimate
1.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.46
Shares Outstanding113,916,756
10 Day Avg. Volume1,278
30 Day Avg. Volume925
Financial Highlights & Ratios
PEG Ratio3.23
Price to Book (P/B)2.83
Price to Sales (P/S)0.70
P/FCF Ratio16.05
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$97.15Price Target Upside13.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)5.35
Revenue Forecast (FY)$13.74B
Bulls Say, Bears Say
Bulls Say
Recurring, High‑margin Technology RevenueA large, recurring software subscriber base provides predictable revenue, higher margin mix, and stronger customer retention. Over 90% recurring revenue and growing ARPU improve revenue visibility and cash conversion, helping stabilize earnings through equipment cycles and supporting cross‑sell.
Scale Distribution With Market Share GainsSignificant scale across dental and medical distribution, plus reported share gains and faster‑growing private/own brands, create durable sourcing advantages and customer reach. This reinforces recurring reorder economics and bargaining power with suppliers, supporting long‑term revenue resilience.
Positive Free Cash Flow And Improving Operating CashConsistent, improving free cash flow provides internal funding for buybacks, reinvestment, and debt reduction. Management guidance that operating cash will exceed net income signals cash generation quality, giving flexibility to execute value‑creation programs and support long‑term capital allocation.
Bears Say
Rising Leverage Reduces Financial FlexibilityMaterial increase in leverage limits strategic optionality and raises interest and refinancing risk. Higher debt loads reduce capacity for acquisitions, capital spending, or cushioning against demand shocks, making the company more sensitive to margin or cash‑flow volatility over a multi‑quarter horizon.
Net Margin Compression Versus HistoryDeclining net margins indicate weaker conversion of sales into profit and reduce the company's earnings power. This constrains reinvestment and limits the payoff from revenue growth, meaning improvements must come from sustained cost reductions or mix shifts to restore historical profitability levels.
Equipment And Diagnostics Demand/ASP PressureWeakness and ASP declines in equipment and lower diagnostic demand reduce higher‑ticket, higher‑margin revenue streams. A shift toward lower‑margin consumables lowers overall mix profitability and makes durable margin expansion harder without structural recovery in equipment and diagnostics markets.
Henry Schein News
0L3C FAQ
What was Henry Schein’s price range in the past 12 months?
Henry Schein lowest share price was $62.29 and its highest was $92.50 in the past 12 months.
What is Henry Schein’s market cap?
Henry Schein’s market cap is $9.77B.
When is Henry Schein’s upcoming earnings report date?
Henry Schein’s upcoming earnings report date is Nov 03, 2026 which is in 85 days.
How were Henry Schein’s earnings last quarter?
Henry Schein released its earnings results on Aug 04, 2026. The company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.03.
Is Henry Schein overvalued?
According to Wall Street analysts Henry Schein’s price is currently Undervalued.
Does Henry Schein pay dividends?
Henry Schein does not currently pay dividends.
What is Henry Schein’s EPS estimate?
Henry Schein’s EPS estimate is 1.36.
How many shares outstanding does Henry Schein have?
Henry Schein has 113,916,756 shares outstanding.
What happened to Henry Schein’s price movement after its last earnings report?
Henry Schein reported an EPS of $1.27 in its last earnings report, beating expectations of $1.24. Following the earnings report the stock price went up 2.822%.
Which hedge fund is a major shareholder of Henry Schein?
Currently, no hedge funds are holding shares in GB:0L3C
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Henry Schein Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$97.15 (13.40% Upside)
$97.15 (13.40% Upside)
Blogger Sentiment
Bullish
GB:0L3C Sentiment 60%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $691.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.86%
Trailing 12-Months
Company Description
Henry Schein
Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repair services. Furthermore, it distributes a broad range of medical supplies, including pharmaceuticals (both branded and generic), vaccines, surgical instruments, diagnostic kits, infection prevention solutions, imaging products, equipment, and nutritional supplements. The Technology and Value-Added Services segment focuses on empowering practices with advanced software, technology, and supplementary solutions. This includes specialized practice management software systems tailored for both dental and medical professionals. Beyond software, it delivers crucial value-added practice support services, such as non-recourse financial assistance, electronic services, comprehensive technology and network infrastructure support, hardware services, ongoing professional development programs, and expert consulting. Established in 1932, Henry Schein, Inc. maintains its corporate headquarters in Melville, New York.
0L3C Company Deck
0L3C Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and financial update: solid top-line growth (6.7%), expanding margins, double-digit non-GAAP EPS growth (15.5%), strong adjusted EBITDA growth (12.7%), and raised full-year guidance. Management reinforced a clear value-creation program with specific savings targets ($125M run-rate by end-2026; $200M+ over time) and early implementation steps producing measurable benefits. Technology and recurring-revenue businesses (Dentrix Ascend / Henry Schein One) showed notable strength and strategic potential. Near-term headwinds include a small decline in U.S. dental equipment, lower point-of-care diagnostic demand, meaningful Q2 restructuring charges ($29M), and reduced remeasurement gains versus prior year, which constrain GAAP clarity and EPS flow-through. Overall, the positive metrics, guidance raise, and credible execution plan outweigh the localized challenges and one-time costs.View all GB:0L3C earnings summaries0L3C Revenue Breakdown
84.48% Global Distribution and Value-Added Services
11.71% Global Specialty Products
5.12% Global Technology
-1.31% Eliminations
0L3C Stock 12 Month Forecast
Average Price Target
$97.15
▲(13.40% Upside)